Figure 2.
Management of hemolysis AEs in PEGASUS.∗If a patient did not respond adequately to the twice-weekly dose of pegcetacoplan (LDH levels ≥2× ULN), dosing could be increased to 1080 mg every 3 days according to the prescribing information.13 CAC, complement-amplifying condition; ECU, eculizumab; HAE, hemolysis adverse event; PEG, pegcetacoplan; RBC, red blood cell.

Management of hemolysis AEs in PEGASUS.∗If a patient did not respond adequately to the twice-weekly dose of pegcetacoplan (LDH levels ≥2× ULN), dosing could be increased to 1080 mg every 3 days according to the prescribing information.13 CAC, complement-amplifying condition; ECU, eculizumab; HAE, hemolysis adverse event; PEG, pegcetacoplan; RBC, red blood cell.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal